526 related articles for article (PubMed ID: 33232723)
21. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
22. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
23. Predicting immunotherapy response through genomics.
Cormedi MCV; Van Allen EM; Colli LM
Curr Opin Genet Dev; 2021 Feb; 66():1-9. PubMed ID: 33307238
[TBL] [Abstract][Full Text] [Related]
24. Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients.
Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Frydecka I; Pawlak E; Szmyrka M; Kosmaczewska A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502204
[TBL] [Abstract][Full Text] [Related]
25. The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer.
Xu JY; Wang WS; Zhou J; Liu CY; Shi JL; Lu PH; Ding JL
Pancreas; 2019 Aug; 48(7):904-912. PubMed ID: 31268976
[TBL] [Abstract][Full Text] [Related]
26. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
27. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
29. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
30. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
31. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
32. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
33. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.
Guram K; Kim SS; Wu V; Sanders PD; Patel S; Schoenberger SP; Cohen EEW; Chen SY; Sharabi AB
Front Immunol; 2019; 10():491. PubMed ID: 30936880
[TBL] [Abstract][Full Text] [Related]
34. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.
Liberini V; Laudicella R; Capozza M; Huellner MW; Burger IA; Baldari S; Terreno E; Deandreis D
Molecules; 2021 Apr; 26(8):. PubMed ID: 33920423
[TBL] [Abstract][Full Text] [Related]
35. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
Christmas BJ; Rafie CI; Hopkins AC; Scott BA; Ma HS; Cruz KA; Woolman S; Armstrong TD; Connolly RM; Azad NA; Jaffee EM; Roussos Torres ET
Cancer Immunol Res; 2018 Dec; 6(12):1561-1577. PubMed ID: 30341213
[TBL] [Abstract][Full Text] [Related]
36. Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
Yan Y; Huang Z; Cai J; Tang P; Zhang F; Tan M; Shen B
Aging (Albany NY); 2020 Dec; 13(2):2780-2802. PubMed ID: 33408272
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer.
Hashemi-Sadraei N; Sikora AG; Brizel DM
Am Soc Clin Oncol Educ Book; 2016; 35():e277-82. PubMed ID: 27249733
[TBL] [Abstract][Full Text] [Related]
38. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
39. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
40. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade.
Nielsen SR; Strøbech JE; Horton ER; Jackstadt R; Laitala A; Bravo MC; Maltese G; Jensen ARD; Reuten R; Rafaeva M; Karim SA; Hwang CI; Arnes L; Tuveson DA; Sansom OJ; Morton JP; Erler JT
Nat Commun; 2021 Jun; 12(1):3414. PubMed ID: 34099731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
